Nectar Lifesciences Limited (NECLIFE.NS) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

-45.1%

₹5.57

vs ₹10.15 price

Levered DCF

₹5.42

After debt service

Piotroski score

3 / 9

Weak

Altman Z-score

—

Rating

C+

Overall 2 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2026	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
P/E	-0.67×	-4.75×	155.68×	-14.77×	21.47×	-5.69×	6.9×	8.3×
P/B	0.34×	0.56×	0.72×	0.34×	0.5×	0.39×	0.19×	0.36×
P/S	97.56×	0.32×	0.46×	0.23×	0.32×	0.27×	0.09×	0.14×
EV / EBITDA	-2.9×	-44.9×	8.21×	10.99×	8.58×	21.14×	5.14×	6.09×
Gross margin	-2936.3%	18.1%	28.6%	3.8%	17.9%	16.7%	9.7%	14.8%
Operating margin	-95.1%	-5.3%	23.1%	-0.3%	6.1%	4.0%	6.7%	7.2%
Net margin	-14568.1%	-6.8%	0.3%	-1.6%	1.5%	-4.7%	1.3%	1.7%
Current ratio	8.4×	1.21×	1.32×	1.38×	1.35×	1.04×	1.29×	1.28×
Debt / equity	0×	0.61×	0.59×	0.71×	0.79×	0.85×	0.69×	0.82×
Interest coverage	-0.05×	-1.19×	4.46×	-0.05×	1.28×	0.6×	1.33×	1.38×
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.3%	0.6%	0.3%
Payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	-1.5%	4.3%	2.8%

Key metrics by fiscal year

Metric	FY2026	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
Return on equity	-50.3%	-11.9%	0.5%	-2.3%	2.3%	-6.9%	2.8%	4.3%
Return on invested capital	-0.2%	-4.0%	6.2%	-0.1%	3.8%	2.7%	6.6%	7.6%
Return on assets	-47.1%	-5.6%	0.2%	-1.1%	1.0%	-3.1%	1.2%	1.8%
Free cash flow yield	-184.1%	23.3%	25.4%	29.0%	13.0%	-2.4%	104.7%	51.0%
Earnings yield	-149.3%	-21.0%	0.7%	-6.8%	4.6%	-17.6%	14.5%	12.1%
Enterprise value	₹840M	₹11B	₹13.8B	₹10.9B	₹13.8B	₹13B	₹9.8B	₹12.8B
Net debt / EBITDA	3.87×	-22.91×	3.65×	7.4×	5.23×	14.33×	3.99×	4.21×
Cash conversion cycle (days)	18	143	200	155	204	178	153	148